XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Revenues $ 3,162.1 $ 2,965.1
Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Regeneron's share of profits in connection with commercialization    
Disaggregation of Revenue [Line Items]    
Revenues 636.5 415.3
Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Sales-based milestones earned    
Disaggregation of Revenue [Line Items]    
Revenues 0.0 50.0
Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Reimbursement for manufacturing of commercial supplies    
Disaggregation of Revenue [Line Items]    
Revenues 161.9 160.8
Sanofi Collaboration Agreement, Antibody | (R&D expense)/Reduction of R&D expense | Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses    
Disaggregation of Revenue [Line Items]    
Revenues (26.4) 26.8
Sanofi Collaboration Agreement, Antibody | SG&A expense | Reimbursement of commercialization-related expenses    
Disaggregation of Revenue [Line Items]    
Revenues 117.6 91.7
Sanofi Collaboration Agreement, Immuno-oncology | Collaboration revenue | Regeneron's share of profits in connection with commercialization | Outside United States    
Disaggregation of Revenue [Line Items]    
Revenues 0.0 2.8
Sanofi Collaboration Agreement, Immuno-oncology | Collaboration revenue | Reimbursement for manufacturing of ex-U.S. commercial supplies    
Disaggregation of Revenue [Line Items]    
Revenues 0.0 2.0
Sanofi Collaboration Agreement, Immuno-oncology | (R&D expense)/Reduction of R&D expense | Reimbursement of R&D expenses    
Disaggregation of Revenue [Line Items]    
Revenues 0.0 21.5
Sanofi Collaboration Agreement, Immuno-oncology | SG&A expense | Reimbursement of commercialization-related expenses    
Disaggregation of Revenue [Line Items]    
Revenues 0.0 19.0
Sanofi Collaboration Agreement, Immuno-oncology | SG&A expense | Regeneron's obligation for its share of Sanofi commercial expenses    
Disaggregation of Revenue [Line Items]    
Revenues 0.0 (9.2)
Sanofi Collaboration Agreement, Immuno-oncology | Cost of goods sold | Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits    
Disaggregation of Revenue [Line Items]    
Revenues 0.0 (32.3)
Sanofi Collaboration Agreement, Immuno-oncology | Other operating income | Amounts recognized in connection with up-front payments received    
Disaggregation of Revenue [Line Items]    
Revenues $ 0.0 $ 18.1